Co-DiagnosticsCODX
CODX
About: Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Employees: 155
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
4.09% more ownership
Funds ownership: 13.83% [Q3] → 17.92% (+4.09%) [Q4]
3% more funds holding
Funds holding: 36 [Q3] → 37 (+1) [Q4]
22% less capital invested
Capital invested by funds: $5.52M [Q3] → $4.3M (-$1.22M) [Q4]
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
68% less call options, than puts
Call options by funds: $97K | Put options by funds: $299K
Research analyst outlook
We haven’t received any recent analyst ratings for CODX.
Financial journalist opinion
Based on 4 articles about CODX published over the past 30 days
Neutral
PRNewsWire
2 hours ago
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results
SALT LAKE CITY , March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023.
Neutral
PRNewsWire
2 weeks ago
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast
SALT LAKE CITY , March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.
Neutral
PRNewsWire
3 weeks ago
Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit
SALT LAKE CITY , March 6, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that on March 4, 2025, the Securities & Governance Litigation Team at BakerHostetler, the legal firm retained to represent the Company, won complete dismissal on summary judgment of a Section 10(b) securities class action that had been pending against the Company in the United States District Court for the District of Utah. See Gelt Trading, Ltd.
Neutral
PRNewsWire
3 weeks ago
Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025
The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV Awareness Day, in Baroda, India SALT LAKE CITY , March 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company and CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will be hosting a symposium to honor International HPV (human papillomavirus) Awareness Day 2025.
Neutral
Benzinga
1 month ago
Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version
On Friday, Co-Diagnostics, Inc. CODX withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test for 510(k) clearance.
Neutral
PRNewsWire
1 month ago
Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance
The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of a test component SALT LAKE CITY , Feb. 21, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, following a collaborative and informative dialogue with the Food and Drug Administration (FDA), the Company has withdrawn its 510(k) application to the FDA for its Co-Dx™ PCR COVID-19 Test on the PCR Pro™*, in favor of submitting an enhanced version of the test for 510(k) clearance. Co-Dx is pleased with the productive engagement with the FDA related to the initial regulatory submission and with the performance of the test in clinical evaluations, including performance data and functionality of the instrument.
Neutral
PRNewsWire
2 months ago
Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025
SALT LAKE CITY , Jan. 7, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be participating in Nasdaq's Live from MarketSite broadcast at the Silicon Slopes Summit 2025 on January 14, 2025. Live from MarketSite is Nasdaq's flagship broadcast opportunity, showcasing innovative leaders and disruptive companies in their fields.
Neutral
PRNewsWire
3 months ago
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility
New oligonucleotide facility is designed to support "Make in India" initiative by synthesizing Co-Primers® in-house. Attendees of new ribbon-cutting event expected to include representatives from NGOs and government leaders SALT LAKE CITY , Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt.
Neutral
Seeking Alpha
4 months ago
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations. Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Jade Montgomery - H.C.
Negative
Zacks Investment Research
4 months ago
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.20 per share a year ago.
Charts implemented using Lightweight Charts™